The Cell and Gene Therapy for Rare Diseases 2026 is a 5-day in-person workshop, scheduled for June 1-5, 2026, and is an intensive educational program focused on the development cycle of Advanced Therapy Medicinal Products (ATMPs).

Hosted by EATRIS in collaboration with the European Rare Diseases Research Alliance (ERDERA), the course is specifically designed for researchers, clinicians, and industry professionals working in the rare disease space. The curriculum covers four critical pillars: scientific and clinical challenges, manufacturing scale-up, regulatory pathways, and HTA/reimbursement strategies. The exact location will be announced closer to the date.